Abstract 66P
Background
Glioblastoma is the most common primary malignancy of the brain, affecting approximately 3 per 100 000 people, with a median overall survival of 15 months. Tumor-associated macrophages comprise up to 30% of the glioblastoma tumor microenvironment (TME) and consist of microglia and monocyte-derived macrophages (MDM). MDM arise from granulocyte-monocyte progenitors (GMP) or monocyte-dendritic cell progenitors (MDP). Our recent work identified a unique macrophage population expressing myeloperoxidase (MPO) and other GMP-associated genes associated with long-term survival in glioblastoma patients. ScRNA-seq analysis suggests that MPO+ macrophages may arise from GMPs and are metabolically distinct from MPO- MDM. Interestingly, adoptive transfer of GMP- versus MDP-derived monocytes into glioma-bearing mice had opposing effects on tumor growth. GMP-lineages specifically delayed tumor growth—aligning with our correlative findings in patients. The role of metabolic changes on the anti-tumor function of MDM of distinct developmental lineages remains unknown. We hypothesize that metabolic differences between GMP- and MDP-derived MDM may shift nutrient partitioning within the TME.
Methods
Bulk RNA-seq of GMP- and MDP-MDM was performed. To functionally assess metabolic differences between GMP- and MDP-MDM, Seahorse XFe96 analysis as well as metabolite analysis of conditioned media will be performed.
Results
Bulk RNA-seq of GMP- and MDP-MDM showed differential expression of many metabolic pathways, notably, a downregulation of the pentose phosphate pathway and aerobic respiration in GMP-MDM compared to MDP-MDM. Furthermore, co-culturing GMP- or MDP-MDM with GL261 glioma cell line suggests GMP-MDM are more phagocytic towards tumor cells. We will perform Seahorse XFe96 analysis and metabolite analysis of the conditioned media from GMP-MDM vs. MDP-MDM to investigate the functional impact of metabolic differences further.
Conclusions
Understanding how metabolic differences of MDM derived from different lineages shift nutrient competition in the TME will lead to a better understanding of the roles of macrophages in the TME.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
30P - Role of microRNA and CDKN2A/p16INK4a expression in the prognostication of oral squamous cell carcinoma
Presenter: Olha Burtyn
Session: Cocktail & Poster Display session
Resources:
Abstract
31P - Identification of proteins associated with mRNA processing and maturation by quantitative proteomic analysis in Indian cervical cancer patients
Presenter: Amrita Mukherjee
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Expression of STAT3 and hypoxia markers in repeatedly resected glioma patients
Presenter: Katerina Dvorakova
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Unraveling the mechanisms of cisplatin resistance in bladder organoid by single cell RNA sequencing
Presenter: Tingting Xie
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - Functional diagnostics and ex-vivo screening of erlotinib and nintedanib in non-small cell lung carcinoma: Implications for multidrug resistance and personalized therapy
Presenter: Jelena Dinić
Session: Cocktail & Poster Display session
Resources:
Abstract
35P - Enhancing efficacy of the MEK inhibitor trametinib in KRAS-mutated colorectal cancer cells
Presenter: Lee Ellis
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Comparison of pelitinib, tepotinib or docetaxel efficacy according to the copy number or gene alteration status of EGFR, MET, HRAS, KRAS and NRAS genes
Presenter: Dae Young Zang
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - NET-mediated radio-resistance in early-stage non-small cell lung cancer
Presenter: Malcolm Ryan
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - The use of antibiotics or proton pump inhibitors and the response to intravesical Bacillus Calmette Guérin therapy in non-muscle-invasive bladder cancer
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - YAP1 promotes sorafenib resistance by activation of TGFβ signaling pathway
Presenter: Chit Lai Chee
Session: Cocktail & Poster Display session
Resources:
Abstract